Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cardiovascular Disease AND Placebo drug

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44337   clinical trials with a EudraCT protocol, of which   7367   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    385 result(s) found for: Cardiovascular Disease AND Placebo drug. Displaying page 11 of 20.
    «« First « Previous 7  8  9  10  11  12  13  14  15  Next» Last»»
    EudraCT Number: 2005-004863-41 Sponsor Protocol Number: SIPHT-001 Start Date*: 2006-10-04
    Sponsor Name:Dept. of Internal Medicine II, University Hospital Giessen
    Full Title: Clinical investigation into efficacy, hemodynamics and tolerability of simvastatin vs placebo in patients with pulmonary arterial hypertension (Shorttitle: SIPHT) Double-blind, randomized, prospe...
    Medical condition: Modified NYHA class II or III patients with Pulmonary Hypertension (PH), ICD: 416.9
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020787 Hypertension pulmonary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-002645-37 Sponsor Protocol Number: KC706-C05 Start Date*: 2006-08-25
    Sponsor Name:Kémia, Inc.
    Full Title: A Phase II randomized double-blind placebo-controlled Study of KC706 in patients with rheumatoid arthritis inadequately controlled with a stable dose of methotrexate
    Medical condition: Active rheumatoid arthritis (RA), patients taking stable doses of methotrexate
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002643-28 Sponsor Protocol Number: B1481020 Start Date*: 2013-12-10
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, LONG-TERM SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH PRIMARY HYPERLIPIDEMIA OR MIXE...
    Medical condition: primary hyperlipidemia or mixed dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004861 10020667 Hyperlipidemia LLT
    18.0 100000004861 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) GB (Completed) ES (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2005-003561-16 Sponsor Protocol Number: TAK-242/01-04-TL-242-011 Start Date*: 2005-12-21
    Sponsor Name:Takeda Europe R&D Centre Ltd
    Full Title: A Pivotal, Multicentre, Multinational, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-242 in Adults with Severe Sepsis
    Medical condition: Severe sepsis
    Disease: Version SOC Term Classification Code Term Level
    8 10040047 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) FI (Prematurely Ended) AT (Prematurely Ended) CZ (Prematurely Ended) SE (Prematurely Ended) ES (Completed) PT (Prematurely Ended) DK (Prematurely Ended) IT (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-002235-60 Sponsor Protocol Number: NN9536-7545 Start Date*: 2023-02-24
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect and safety of semaglutide 7.2 mg once-weekly in participants with obesity and type 2 diabetes
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) SK (Completed) HU (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000530-29 Sponsor Protocol Number: CONVERT-AF Start Date*: 2014-08-19
    Sponsor Name:University Hospital Basel
    Full Title: Canakinumab for the Prevention of Recurrences After Electrical Cardioversion in Patients With Persistent Atrial Fibrillation (CONVERT-AF) Trial - A Randomized Double Blind Placebo Controlled Study
    Medical condition: Atrial Fibrillation
    Disease: Version SOC Term Classification Code Term Level
    16.1 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-005615-32 Sponsor Protocol Number: SPIHF-203 Start Date*: 2016-05-18
    Sponsor Name:Stealth BioTherapeutics Inc.
    Full Title: A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effects of 4 Weeks Treatment with Subcutaneous Elamipretide on Left Ventricular Function in Subjects with Stable Heart...
    Medical condition: Heart failure with preserved ejection fraction (HFpEF)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003951-39 Sponsor Protocol Number: GS-US-223-1017 Start Date*: 2019-12-09
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Di...
    Medical condition: Diabetic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002642-37 Sponsor Protocol Number: B1481019 Start Date*: 2014-01-24
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPID...
    Medical condition: primary hyperlipidemia or mixed dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004861 10020667 Hyperlipidemia LLT
    18.1 100000004861 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-004142-11 Sponsor Protocol Number: A011-11 Start Date*: 2021-05-12
    Sponsor Name:Acceleron Pharma Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy...
    Medical condition: Pulmonary Arterial Hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) FR (Completed) BE (Completed) NL (Completed) AT (Completed) PL (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000295-42 Sponsor Protocol Number: GFT505-212-7 Start Date*: 2012-09-11
    Sponsor Name:GENFIT
    Full Title: A Multicentre, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GFT505 once daily on Steatohepatitis in Patients with Non-Alcoholic Steatohepatitis (NASH).
    Medical condition: Patients with Non-Alcoholic Steatohepatitis (NASH)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) ES (Completed) GB (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-000552-25 Sponsor Protocol Number: DS9231-A-U201 Start Date*: 2017-08-07
    Sponsor Name:Daiichi Sankyo Inc.
    Full Title: Evaluation of Safety and Thrombolytic Effect of Ascending Doses of DS-9231 (TS23) in Subjects with Intermediate-Risk (sub-massive) Acute Pulmonary Embolism (PE)
    Medical condition: DS9231, also known as TS23, is an inhibitor of alpha2-antiplasmin, incrasing plasmin acitivy and enhances fibrinolysis (thrombolysis) and intended to be used for the treatment of patients with Inte...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10037379 Pulmonary embolism and thrombosis HLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037377 Pulmonary embolism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002312-27 Sponsor Protocol Number: 13-031 Start Date*: 2013-08-14
    Sponsor Name:Zealand Pharma
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess Clinical Efficacy and Safety of Danegaptide in Patients with ST-Elevation Myocardial Infarction undergoing Primary Per...
    Medical condition: The treatment of acute myocardial infarction, AMI is aimed at enabling the return of blood flow to the ischemic myocardium, thereby limiting the size of the infarct. However the reperfusion by itse...
    Disease: Version SOC Term Classification Code Term Level
    16.1 10047065 - Vascular disorders 10063837 Reperfusion injury PT
    16.1 100000004849 10064345 ST segment elevation myocardial infarction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-000085-42 Sponsor Protocol Number: LLB-2019-03 Start Date*: Information not available in EudraCT
    Sponsor Name:LABO'LIFE Belgium sprl
    Full Title: Randomized, placebo-controlled, double blind study to evaluate the efficacy of 2LEBV® and 2LXFS® on asthenia in patients with an EBV infection. EBVAST Study
    Medical condition: Epstein-Barr Virus infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10014077 EBV infection LLT
    23.0 100000004862 10014078 EBV infection reactivation LLT
    21.1 100000004848 10056906 EBV antibody positive LLT
    21.0 100000004848 10056907 EBV antigen positive LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-003552-21 Sponsor Protocol Number: I7I-MC-XNAA Start Date*: 2014-05-27
    Sponsor Name:Eli Lilly and Company
    Full Title: Comparison of the Oxyntomodulin Analog, LY2944876, to Once-Weekly Exenatide and to Placebo in Patients with Type 2 Diabetes.
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2010-021922-36 Sponsor Protocol Number: 2010-352-UREMINC Start Date*: 2011-05-23
    Sponsor Name:Department of Nephrology, Rigshospitalet, University of Copenhagen
    Full Title: Safety and effect of liraglutide in patients with type 2 diabetes and severe renal insufficiency.
    Medical condition: 1) Patients with type 2 diabetes (T2D) and no or severely reduced kidney function, depending on chronic dialysis treatment. 2) Patients with T2D and normal kidney function.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10041244 - Social circumstances 10012347 Dependence on renal dialysis LLT
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    14.1 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000126-19 Sponsor Protocol Number: SPIHF-204 Start Date*: 2016-08-01
    Sponsor Name:Stealth BioTherapeutics Inc.
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment with Elamipretide in Patients Hospitalized with Congestion due to Hear...
    Medical condition: Congestive heart failure
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004849 10010684 Congestive heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) NL (Completed) ES (Completed) HU (Completed) GB (Completed) BG (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001516-54 Sponsor Protocol Number: GS-US-259-0103 Start Date*: 2011-11-24
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Cross-over Trial to Evaluate the Effects of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging.
    Medical condition: Coronary artery disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FI (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-001633-40 Sponsor Protocol Number: ESRA Start Date*: 2022-03-07
    Sponsor Name:Thoraxklinik Heidelberg gGmbH
    Full Title: Efficacy and safety of riociguat (MK-4836) in incipient pulmonary vascular disease as an indicator for early pulmonary arterial Hypertension Doubleblind, randomized, multicentre, multinational, pla...
    Medical condition: early pulmonary vascular disease, defined as either a) mean pulmonary arterial pressure (mPAP) ≥25 mmHg with pulmonary vascular resistance (PVR) ≥2 to <3 WU and pulmonary arterial wedge pressure (P...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10037455 Pulmonary vascular disorders NEC HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-002517-11 Sponsor Protocol Number: CD0001 Start Date*: 2012-02-22
    Sponsor Name:UCB BIOSCIENCES GmbH
    Full Title: A multi-centre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, tolerability, and pharmacokinetic of olokizumab administered subcutaneously to subjects with mod...
    Medical condition: Moderate to severe Crohn’s disease
    Disease: Version SOC Term Classification Code Term Level
    15.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    15.0 10017947 - Gastrointestinal disorders 10011403 Crohn's disease aggravated LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) HU (Prematurely Ended) CZ (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 7  8  9  10  11  12  13  14  15  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 22 08:13:46 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA